ConcertAI
NativePrivateUpdated November 3, 2026Real-world-data/oncology analytics for cancer research
- Website
- www.concertai.com
- CEO
- Eron Kelly
- Founded
- 2017
- HQ
- Cambridge, United States
- Total Funding
- $300M
- Employees
- 501-1000
Products & Offerings
CARAai
ConcertAI's multi-LLM agentic AI platform, built with NVIDIA, that powers its clinical development, real-world evidence and commercial applications.
Accelerated Clinical Trials (ACT)
Enterprise agentic AI workflow platform that helps sponsors and CROs with protocol design, site selection, activation, recruitment and study monitoring.
Precision360
Real-world dataset for oncology research that links clinical, genomic and other data from ConcertAI's provider network, including Foundation Medicine data.
CancerLinQ Suite
Point-of-care oncology intelligence and quality platform for cancer centers, with AI-driven clinical trial matching added at ASCO 2026.
Cadence Suite
AI-native platform for pharma commercial teams that tracks the patient journey and flags access barriers to therapy.
Executive Summary
What they do
- Licenses oncology real-world data linked to clinical, genomic and imaging records
- Sells agentic AI SaaS for designing trials, choosing sites and recruiting patients
- Runs CancerLinQ point-of-care intelligence and TeraRecon AI tools for medical imaging
Why it matters
- Says its ACT platform can cut overall trial timelines by 10-20 months
- Foundation Medicine partnership adds genomic data linked to clinical records for research
- CARAai platform built with NVIDIA brings multi-LLM agents to oncology workflows
Best fit
- Pharma and biotech oncology teams running real-world evidence and trial programs
- CROs and research site networks that want AI trial matching and enrollment
- Cancer centers and oncology practices looking for quality and decision support
Watch-outs
- Unclear who leads the company after the announced CEO transition
- Last disclosed funding was a $150M Series C in 2022
- Employee reviews mention repeated layoffs, offshoring and data-quality concerns
Latest News
GetLatka · 2 months ago
PositiveUnlock Full Intelligence
Pro members get the complete briefing
- Complete analyst verdict
- Risk assessment
- All 6 Bluescore dimension scores
- Traction signals
- Bluescore history & momentum tracking
- Unlimited company access
ConcertAI is one of the few independent oncology real-world data vendors at scale. It offers a broad stack covering linked clinical-genomic data, CancerLinQ and agentic AI trial tools, which puts it alongside Flatiron Health, Tempus and IQVIA on most oncology shortlists. Buyers should run a structured evaluation that checks data provenance, completeness and refresh cadence. They should also test the claimed trial-acceleration results on their own studies and confirm leadership stability and long-term financial support before signing multi-year contracts.
Signal Provenance
Latest observation date and source for each signal category
| Signal Category | Last Updated | Source |
|---|---|---|
Funding Signals Last funding round, Funding stage | Oct 31, 2026 | Montclare research agents |
Hiring Velocity Headcount, Headcount growth | Nov 3, 2026 | Montclare research agents |
Technical Output Research papers, GitHub activity | Nov 1, 2026 | Montclare research agents |
News Sentiment News mentions, News sentiment | Nov 3, 2026 | Montclare research agents |
Partnership Signals Enterprise partnerships, Distribution partners | Oct 9, 2026 | Montclare research agents |
Revenue Indicators ARR estimate, Revenue growth | Nov 3, 2026 | Montclare research agents |
Leadership Signals CEO tenure, Founder-led | Nov 3, 2026 | Montclare research agents |
Competitive Position Category rank, Market share | Nov 3, 2026 | Montclare research agents |
Why this Bluescore?
6 dimensions, each scored 0–10 against all — companies. Each adds its weight × score to the Bluescore — see methodology